Healthcare Sales & Marketing Network News: pregnancy test

Searching News Database: pregnancy test

HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA

HSMN NewsFeed - 5 Nov 2019
Regeneron Provides Updates on Phase 3 Libtayo(R) (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Oct 2019
FDA Grants Ofev(R) Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
Biopharmaceuticals FDA

HSMN NewsFeed - 28 May 2019
True Diagnostics, Inc. Receives FDA 510(k) Clearance to Market VeriClear(TM) Digital Test Device for Early Result Pregnancy
Diagnostics FDA

HSMN NewsFeed - 18 Mar 2019
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 21 Aug 2018
Siklos(R), the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now available in retail pharmacies
Biopharmaceuticals Product Launch

HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 Apr 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV(R) (telavancin) at 2018 ECCMID(TM) Conference
Biopharmaceuticals

HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Dec 2017
Lia Diagnostics Announces FDA Clearance Of The First And Only Flushable, Biodegradable Pregnancy Test
Diagnostics FDA

HSMN NewsFeed - 6 Sep 2017
Actelion Receives FDA Approval Of TRACLEER(R) (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Dec 2016
Novelion Therapeutics Subsidiary, Aegerion Pharmaceuticals, Enters Into Licensing Agreement With Amryt Pharma for LOJUXTA(R) (lomitapide)
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 24 Oct 2016
Efficacy of Ofev(R) (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST
Biopharmaceuticals

HSMN NewsFeed - 22 Jul 2016
VIVUS Announces Favorable Markman Ruling in Qsymia(R) Patent Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 15 Jul 2016
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 May 2016
Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV(R) (telavancin)
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Jan 2016
Impax Receives Approval of EMVERM(TM) (mebendazole) Chewable Tablets, 100 mg
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Jul 2015
FDA approves Novartis drug Odomzo(R) (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Apr 2014
Gilead’s Sovaldi(R) Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease
Biopharmaceuticals

HSMN NewsFeed - 10 Apr 2014
Gilead Announces Results from Study of Sovaldi(R) for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy
Biopharmaceuticals

HSMN NewsFeed - 20 Jan 2014
Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 15 Jan 2014
Antares Pharma Announces Availability of OTREXUP (Methotrexate) Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis (pJIA) in Children
Biopharmaceuticals Drug Delivery Product Launch

HSMN NewsFeed - 6 Dec 2013
U.S. Food and Drug Administration Approves Gilead’s Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Nov 2013
Vertex Sells INCIVO(R) Product Royalty Rights for $152 Million
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2013
Oral Anti-Cancer Therapy Pomalidomide Celgene Receives Positive CHMP Opinion as Treatment for Patients with Relapsed and Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 1 May 2013
New Guidelines From American Association of Clinical Endocrinologists Recommend Medical Treatment of Obesity
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 21 Feb 2013
Valeant Pharmaceuticals Acquires U.S. Rights to Targretin(R) from Eisai Inc.
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 21 Sep 2012
VIVUS Provides Update on the Review of the Qsiva Marketing Authorization Application
Biopharmaceuticals Regulatory

HSMN NewsFeed - 30 Jan 2012
Curis Announces FDA Approval of Erivedge(TM) (vismodegib) Capsule as First Treatment for Advanced Basal Cell Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Sep 2011
Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSA
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 May 2011
FDA Approves INCIVEK(TM) (telaprevir) for People with Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 31 Mar 2011
VICTRELIS(TM) (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control
Biopharmaceuticals

HSMN NewsFeed - 31 Aug 2010
Quidel Announces FDA Clearance of Its RapidVue(R) hCG Pregnancy Lateral Flow Diagnostic Test
Diagnostics FDA

HSMN NewsFeed - 18 May 2010
AccuVein Signs Exclusive Distribution Agreement in India to Sell Vein Illumination Device
Devices Distribution

HSMN NewsFeed - 3 May 2010
Basilea's Toctino(R) receives marketing authorization in Italy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 18 Mar 2010
MicroPhage, Inc. appoints Alene A. Campbell as CEO
Diagnostics Personnel

HSMN NewsFeed - 27 Nov 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Nov 2009
Basilea's Toctino(R) receives marketing authorization in Canada
Biopharmaceuticals Regulatory

HSMN NewsFeed - 5 Nov 2009
Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
Biopharmaceuticals

HSMN NewsFeed - 14 Oct 2009
Basilea's Toctino(R) receives marketing authorization in Switzerland
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 5 Oct 2009
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Oct 2009
Astellas and Theravance Announce Approval of VIBATIV(TM) (telavancin) in Canada for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals Regulatory

HSMN NewsFeed - 5 May 2009
Basilea's Toctino(R) receives marketing authorization in Spain
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 29 Apr 2009
Basilea's Toctino(R) Receives Marketing Authorization in Netherlands
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 17 Mar 2009
Basilea's Toctino(R) receives marketing authorization in Austria
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 11 Mar 2009
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Mar 2009
Basilea's Toctino(R) Receives Marketing Authorization in Belgium and Luxemburg
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 27 Jan 2009
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Biopharmaceuticals

HSMN NewsFeed - 17 Dec 2008
Basilea Pharmaceutica opens U.S. phase III study on alitretinoin for the treatment of severe chronic hand eczema
Biopharmaceuticals Dermatology

HSMN NewsFeed - 24 Nov 2008
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 28 Oct 2008
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals

HSMN NewsFeed - 20 Jun 2008
Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
Biopharmaceuticals

HSMN NewsFeed - 29 May 2008
Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation
Biopharmaceuticals

HSMN NewsFeed - 27 May 2008
AMITIZA(R) (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 21 May 2008
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Biopharmaceuticals

HSMN NewsFeed - 17 Apr 2008
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 16 Apr 2008
Schering-Plough Announces Imperfect Contraceptive Use Impacts Women's Emotional Well-Being
Biopharmaceuticals

HSMN NewsFeed - 27 Mar 2008
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Mar 2008
ContraVac Receives FDA Approval for Post-Vasectomy Home Sperm Test
Diagnostics

HSMN NewsFeed - 14 Jan 2008
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Biopharmaceuticals

HSMN NewsFeed - 15 Nov 2007
PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 2 Nov 2007
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Biopharmaceuticals

HSMN NewsFeed - 2 Nov 2007
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Biopharmacetuicals

HSMN NewsFeed - 30 Oct 2007
Significant New Data on Roche's PEGASYS(R) and Hepatitis C Pipeline Compounds to be Featured at 58th Annual AASLD Meeting
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2007
Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2007
Gilead Announces New LetairisTM (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals

HSMN NewsFeed - 24 Sep 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 13 Sep 2007
Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
Biopharmaceuticals

HSMN NewsFeed - 10 Sep 2007
Aspreva Provides Update On Lupus Nephritis Development Program
Biopharmaceuticals

HSMN NewsFeed - 30 Jul 2007
Lybrel, First Low Dose Combination Oral Contraceptive with Unique 365-Day Dosing, Now Available in U.S.
Biopharmaceuticals

HSMN NewsFeed - 27 Jun 2007
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
Biopharmaceuticals

HSMN NewsFeed - 25 Jun 2007
PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory

HSMN NewsFeed - 15 Jun 2007
U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Biopharmaceuticals FDA

HSMN NewsFeed - 30 May 2007
Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Arterial Hypertension
Biopharmaceuticals Regulatory

HSMN NewsFeed - 22 May 2007
FDA Approves Lybrel, First Low Dose Combination Oral Contraceptive Offering Women the Opportunity to Be Period-Free Over Time
Biopharmaceuticals FDA

HSMN NewsFeed - 21 May 2007
PEGASYS(R) Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered ''Cured''
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 21 May 2007
Data Suggest that PEGASYS(R) May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron(R)
Biopharmaceuticals

HSMN NewsFeed - 21 May 2007
New Study Demonstrates That Lubiprostone May Improve Symptom Relief Rates in Adults With Irritable Bowel Syndrome With Constipation (IBS-C)
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 17 May 2007
Inverness Medical Innovations and Procter & Gamble Form Consumer Diagnostics Joint Venture - SPD Swiss Precision Diagnostics GmbH
Diagnostics

HSMN NewsFeed - 7 May 2007
Early Results of the CellCept(R) Spare the Nephron Study Examine Kidney Function
Biopharmaceuticals

HSMN NewsFeed - 30 Apr 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(Tm) and REBETOL(R) Combination Therapy for Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Apr 2007
Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 5 Apr 2007
PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Feb 2007
Takeda and TAP to Promote Sucampo's AMITIZA(R) in the United States
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 8 Feb 2007
Cholestech Corporation Launches New Dermatology Kit for In-office Cholesterol, Liver and Pregnancy Screening
Diagnostics Dermatology

HSMN NewsFeed - 6 Nov 2006
Matritech and Inverness Medical Innovations Sign Agreements for the Manufacturing and OTC Distribution of the NMP22(R) BladderChek(R) Test
Diagnostics Oncology Distribution

HSMN NewsFeed - 27 Oct 2006
Customizing Treatment with PEGASYS(R) May Improve Chances for Success in Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2006
Roche Oral Polymerase Inhibitor R1626 Shows Strong Antiviral Activity in Chronic Hepatitis C Patients in Early Trial
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2006
Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating Hepatitis C Patients Who Failed Previous Combination Therapy Presented at AASLD
Biopharmaceuticals

HSMN NewsFeed - 26 Oct 2006
Aspreva Pharmaceuticals Announces Preliminary Results of Phase III Trial of CellCept for Myasthenia Gravis
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2006
AMITIZA(TM) (lubiprostone) Phase III Constipation Trial Results Demonstrate Improvements in Symptoms of Irritable Bowel Syndrome With Constipation
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 13 Oct 2006
Roche Advances Oral Polymerase Inhibitor into Phase II Study in Patients with Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 2 Jun 2006
Encysive Pharmaceuticals' Thelin(TM) (sitaxentan sodium) Receives Positive Opinion From European Authorities
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 May 2006
Actelion: ATS Presentation Highlights Strong Rationale for a Morbidity/Mortality Study with Bosentan in Idiopathic Pulmonary Fibrosis
Biopharmaceuticals

HSMN NewsFeed - 23 May 2006
Schering-Plough Initiates PEG-INTRON 'PROTECT' Study in Liver Transplant Patients with Recurrent Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 21 May 2006
New Study Demonstrates That AMITIZA(TM) (lubiprostone) May Help Improve Symptoms of Irritable Bowel Syndrome With Constipation
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 21 May 2006
AMITIZA(TM) (Lubiprostone) Shown Effective and Well-Tolerated in People Older than Age 65, a Population Considerably Affected by Chronic Idiopathic Constipation
Biopharmaceuticals Gastroenterology

Return to NewsFeed

Additional items found! 53

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 53 additional stories matching:
pregnancy test
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.